Filana Therapeutics (FLNA) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Filana Therapeutics (FLNA) over the past year, losing 68.9% versus a loss of 79.6%. Filana Therapeutics is the larger company by market cap ($40.1 million vs $38.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | MGX |
|---|---|---|
| Share price | $0.8292 | $1.01 |
| Market cap | $40.06M | $37.97M |
| 1-day change | +1.92% | +1.19% |
| YTD return | -58.91% | -38.69% |
| 1-year return | -79.56% | -68.87% |
| 5-year return | -98.36% | — |
| EPS (TTM) | $-0.87 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $3.95 |
| 52-week low | $0.67 | $0.96 |
| Distance from 52-week high | -83.35% | -74.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +683.89% | +596.52% |
| Average volume | 2.03M | 158.27K |
| Shares outstanding | 48.31M | 37.78M |
| Employees | 17 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed FLNA by 10.7 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
FLNA vs MGX FAQ
Which is bigger, Filana Therapeutics or Metagenomi Therapeutics?
Filana Therapeutics (FLNA) is larger, with a market capitalization of $40.06M compared with $37.97M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, FLNA or MGX?
MGX returned -68.87% over the past 12 months, compared with -79.56% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and Metagenomi Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Filana Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Metagenomi Therapeutics.